



Ultra Low Dosage Zoledronic Acid For Treatment Of Retinal Disease

[View U.S. Patent Application Publication No. US-2025-0295678 in PDF format.](#)

WARF: P230197US03

Inventors: Aparna Lakkaraju, Li Xuan Tan, Colin Germer

The Invention

UW-Madison and UC-San Francisco researchers have developed a treatment for macular degeneration that uses low doses of the clinically approved molecule, zoledronic acid, which is used to treat bone diseases. Their data shows that zoledronic acid is 2,000 more potent in efficacy in their animal model as compared to their previously tested compound, desipramine.

Tech Fields

- [Therapeutics & Vaccines : Ocular](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847